SomaLogic
Boulder
About SomaLogic
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $956.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Sep 2021)
- Ticker: nasdaq:SLGC
- Website: somalogic.com
- Phone: +1 303-625-9000
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/somalogic-114999 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.